GRI 可持续发展报告标准（GRI Standards，以下简称"GRI标准"） 2021版将于2023年1月1日正式生效。GRI标准2021中文版也将于2022年第三季度发布，这意味着相关的中国企业需要提前了解新版标准中对可持续发展信息披露的要求，并做出积极回应以及建立起符合GRI新标准的 ...

GRI Bio (GRI) announced the presentation of preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis. The data were ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, April 01, 2025 ...

LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...

GRI Bio reports positive interim results for GRI-0621 in IPF treatment; patient enrollment nearing completion, cash runway extended to Q3 2025. Cash runway, although extended by a recent public ...

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed ...

The revision came at an unprecedented time. The COVID-19 pandemic highlighted many gaps in understanding the impact of our supply chains on social structures and communities; revealing deep inequities ...

Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the ...